12 Month Price Forecast For VKTX
Distance to VKTX Price Forecasts
VKTX Price Momentum
🤔 Considering Viking Therapeutics (VKTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 3:49 PM UTC
VKTX Analyst Ratings & Price Targets
Based on our analysis of 20 Wall Street analysts, VKTX has a consensus that is bullish. The median price target is $110.00, with forecasts ranging from $74.00 to $164.00. Currently, there are 15 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With VKTX currently trading at $34.05, the median price forecast suggests a 223.1% upside. The most optimistic forecast comes from at , projecting a 381.6% upside, while Biren Amin at Piper Sandler provides the most conservative target, suggesting a 117.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VKTX Analyst Consensus
VKTX Price Target Range
Latest VKTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VKTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $102.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Dec 2, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $74.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Nov 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $102.00 |
| Nov 22, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Initiates | $109.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $102.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Oct 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Sep 25, 2024 | Oppenheimer | Jay Olson | Outperform | Reiterates | $138.00 |
| Sep 12, 2024 | Morgan Stanley | Michael Ulz | Overweight | Reiterates | $105.00 |
| Sep 11, 2024 | JP Morgan | Hardik Parikh | Overweight | Initiates | $80.00 |
| Jul 25, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Jul 25, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $118.00 |
| Jun 27, 2024 | Morgan Stanley | Michael Ulz | Overweight | Initiates | $105.00 |
| Jun 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $90.00 |
| Jun 17, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $120.00 |
Stocks Similar to Viking Therapeutics Inc
The following stocks are similar to Viking Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Viking Therapeutics Inc (VKTX) Financial Data
Viking Therapeutics Inc has a market capitalization of $3.79B with a P/E ratio of -36.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -15.5%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Viking Therapeutics Inc (VKTX) Company Overview
About Viking Therapeutics Inc
Develops therapies for metabolic and endocrine disorders.
The company focuses on developing innovative biopharmaceuticals targeting metabolic and endocrine disorders, generating revenue primarily through clinical advancements and potential future commercialization of its drug candidates. Its lead product, VK2809, is in advanced clinical trials, indicating a path toward market entry and potential sales.
Founded in 2012 and based in San Diego, Viking Therapeutics is advancing multiple drug candidates through various stages of clinical trials, addressing significant medical needs such as non-alcoholic fatty liver disease and type 2 diabetes. The company’s diverse pipeline positions it well for growth within the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Dr. Brian Lian Ph.D.
Country
United States
IPO Year
2015
Website
www.vikingtherapeutics.comViking Therapeutics Inc (VKTX) Latest News & Analysis
Palantir Technologies (NASDAQ:PLTR) is recognized as a leading pure-play stock in the artificial intelligence sector.
Palantir's designation as a top AI stock highlights its potential for growth and innovation, attracting investor interest in the booming AI sector.
The obesity drug market is rapidly growing, driven by effective and safe medications like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, which are seeing increased demand.
The obesity drug market's rapid growth and proven efficacy indicate strong potential for revenue increases, benefiting companies like Eli Lilly and Novo Nordisk, which could enhance stock performance.
Viking's obesity-drug program is advancing, and management is considering potential manufacturing partnerships.
Viking's advancements in its obesity-drug program and potential manufacturing partnerships could enhance revenue prospects and market share, positively impacting stock performance.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
3 days agoWall Street analysts' recommendations influence investor decisions on buying, selling, or holding stocks, with changes in ratings impacting stock prices significantly.
Analyst ratings directly influence stock prices, impacting investment decisions. Changes in recommendations can signal potential gains or risks, affecting market sentiment and trading behavior.
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
1 day agoViking Therapeutics, Inc. (VKTX) closed at $32.87, reflecting a 0.67% increase from the previous trading day.
Viking Therapeutics' slight price increase signals market confidence, which may attract more investors and influence stock momentum.
Pomerantz LLP is investigating claims for Viking Therapeutics, Inc. (NASDAQ:VKTX) investors. Interested parties can contact Danielle Peyton for more information.
The investigation signals potential legal issues for Viking Therapeutics, which may impact stock performance and investor confidence.
Frequently Asked Questions About VKTX Stock
What is Viking Therapeutics Inc's (VKTX) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Viking Therapeutics Inc (VKTX) has a median price target of $110.00. The highest price target is $164.00 and the lowest is $74.00.
Is VKTX stock a good investment in 2025?
According to current analyst ratings, VKTX has 15 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.05. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for VKTX stock?
Wall Street analysts predict VKTX stock could reach $110.00 in the next 12 months. This represents a 223.1% increase from the current price of $34.05. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viking Therapeutics Inc's business model?
The company focuses on developing innovative biopharmaceuticals targeting metabolic and endocrine disorders, generating revenue primarily through clinical advancements and potential future commercialization of its drug candidates. Its lead product, VK2809, is in advanced clinical trials, indicating a path toward market entry and potential sales.
What is the highest forecasted price for VKTX Viking Therapeutics Inc?
The highest price target for VKTX is $164.00 from at , which represents a 381.6% increase from the current price of $34.05.
What is the lowest forecasted price for VKTX Viking Therapeutics Inc?
The lowest price target for VKTX is $74.00 from Biren Amin at Piper Sandler, which represents a 117.3% increase from the current price of $34.05.
What is the overall VKTX consensus from analysts for Viking Therapeutics Inc?
The overall analyst consensus for VKTX is bullish. Out of 20 Wall Street analysts, 15 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $110.00.
How accurate are VKTX stock price projections?
Stock price projections, including those for Viking Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
